Cabot (NYSE:CBT) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Cabot from “hold” to “buy,” giving the specialty chemicals company a more bullish analyst signal.
• Other analysts remain mixed: Mizuho and UBS raised price targets but kept neutral ratings, while Jefferies maintained a buy. Overall, Cabot still carries an average Hold rating with a $76.25 target price.
• Cabot reported better-than-expected quarterly EPS of $1.61 versus $1.47 estimates, though revenue fell 3.4% year over year. The stock recently traded near $85.71, close to its 12-month high of $86.04.

Cabot (NYSE:CBT - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

Several other research analysts have also recently weighed in on CBT. Mizuho boosted their target price on Cabot from $75.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday. Jefferies Financial Group restated a "buy" rating and set a $85.00 target price on shares of Cabot in a report on Wednesday, February 4th. UBS Group boosted their target price on Cabot from $81.00 to $86.00 and gave the stock a "neutral" rating in a report on Friday. Finally, Zacks Research upgraded Cabot from a "strong sell" rating to a "hold" rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cabot currently has an average rating of "Hold" and an average target price of $76.25.

Cabot Price Performance

NYSE:CBT opened at $85.71 on Friday. Cabot has a 12 month low of $58.33 and a 12 month high of $86.04. The stock has a 50 day moving average of $73.94 and a two-hundred day moving average of $70.43. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 0.51. The firm has a market cap of $4.42 billion, a P/E ratio of 16.20, a price-to-earnings-growth ratio of 10.75 and a beta of 0.78.

Cabot (NYSE:CBT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.47 by $0.14. Cabot had a return on equity of 21.33% and a net margin of 7.97%.The company had revenue of $904.00 million during the quarter, compared to analyst estimates of $900.31 million. During the same period in the previous year, the business earned $1.90 EPS. Cabot's quarterly revenue was down 3.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. On average, analysts expect that Cabot will post 6.25 earnings per share for the current fiscal year.

Institutional Trading of Cabot

Several institutional investors have recently made changes to their positions in CBT. Norges Bank purchased a new stake in shares of Cabot during the 4th quarter valued at approximately $49,662,000. AQR Capital Management LLC raised its position in shares of Cabot by 123.0% during the 2nd quarter. AQR Capital Management LLC now owns 867,946 shares of the specialty chemicals company's stock valued at $65,096,000 after buying an additional 478,702 shares during the period. UBS Group AG raised its position in shares of Cabot by 186.7% during the 3rd quarter. UBS Group AG now owns 593,510 shares of the specialty chemicals company's stock valued at $45,136,000 after buying an additional 386,514 shares during the period. Pacer Advisors Inc. raised its position in shares of Cabot by 3,165.7% during the 4th quarter. Pacer Advisors Inc. now owns 229,252 shares of the specialty chemicals company's stock valued at $15,195,000 after buying an additional 222,232 shares during the period. Finally, American Century Companies Inc. raised its position in shares of Cabot by 8.4% during the 3rd quarter. American Century Companies Inc. now owns 1,805,393 shares of the specialty chemicals company's stock valued at $137,300,000 after buying an additional 140,665 shares during the period. Hedge funds and other institutional investors own 93.18% of the company's stock.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.